Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically

You may also be interested in...



Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference

Genzyme depicts itself as the picture of health with enzyme replacement therapy business returning to normal after manufacturing woes.

Astellas Wins OSI But Victory Comes At A Price

Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17, 2010 with a definitive merger agreement that has the unanimous support of both companies' boards. The victory cost $4 billion, about $500 million more than the original hostile bid which Astellas launched in late February ("The Pink Sheet" DAILY, March 1, 2010)

Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses

Japan's largest drug company Takeda hopes to minimize the impact of looming patent expirations in the U.S. by relying on mergers and acquisitions to increase its pipeline and extend its territory coverage, especially in emerging countries

Related Content

UsernamePublicRestriction

Register

SC076258

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel